| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Kar Neng Lai | |
| Desmond Yat Hin Yap | |||
| P2860 | cites work | Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus | Q74298111 |
| Drug-induced systemic lupus erythematosus associated with etanercept therapy | Q77696979 | ||
| The role of BLyS/BLyS receptors in anti-chromatin B cell regulation | Q79974110 | ||
| Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families | Q80033225 | ||
| Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18 | Q80419619 | ||
| Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells | Q80427973 | ||
| Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases | Q80510869 | ||
| Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis | Q82975773 | ||
| Interleukin-6 release from peripheral mononuclear cells is associated to disease activity and treatment response in patients with lupus nephritis | Q84769392 | ||
| Drug-induced systemic lupus erythematosus and TNF-alpha blockers | Q94077789 | ||
| TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease | Q22254041 | ||
| Molecular cloning and characterization of a novel stromal cell-derived cDNA encoding a protein that facilitates gene activation of recombination activating gene (RAG)-1 in human lymphoid progenitors | Q24311050 | ||
| CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene | Q24315956 | ||
| Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus | Q24530690 | ||
| Rationale for interleukin-6 blockade in systemic lupus erythematosus | Q24564990 | ||
| Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history | Q27485637 | ||
| Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells | Q27860460 | ||
| BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator | Q28139180 | ||
| Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency | Q28190857 | ||
| Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus | Q28212039 | ||
| Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17 | Q28213628 | ||
| Transforming growth factor-beta induces development of the T(H)17 lineage | Q28237370 | ||
| High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus | Q28307075 | ||
| IL-23 drives a pathogenic T cell population that induces autoimmune inflammation | Q29547525 | ||
| IL-17 family cytokines and the expanding diversity of effector T cell lineages | Q29619361 | ||
| Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus | Q30828464 | ||
| Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. | Q33951524 | ||
| B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses | Q33968482 | ||
| Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy | Q33973488 | ||
| Interleukin 6 promotes murine lupus in NZB/NZW F1 mice | Q34228814 | ||
| CD4+ CD25+ suppressor T cells: more questions than answers | Q34716304 | ||
| Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice | Q34729932 | ||
| Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. | Q34765324 | ||
| Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys | Q34892862 | ||
| IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation | Q46043693 | ||
| In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells | Q46114316 | ||
| Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial | Q46353641 | ||
| Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis | Q46376254 | ||
| Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. | Q46503835 | ||
| Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. | Q47368420 | ||
| IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice | Q47901598 | ||
| Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody | Q47943840 | ||
| Renal expression of IL-6 and TNFalpha genes in lupus nephritis | Q48024829 | ||
| Raised expression of cytokine receptor gp130 subunit on peripheral lymphocytes of patients with active lupus. A useful tool for monitoring the disease activity? | Q51824324 | ||
| Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. | Q53356768 | ||
| Cytokine balance in kidney tissue from lupus nephritis patients | Q53655942 | ||
| Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies | Q56774177 | ||
| An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway | Q57230082 | ||
| Cytokine production, serum levels and disease activity in systemic lupus erythematosus | Q57351067 | ||
| NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells | Q64140399 | ||
| Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice | Q67975304 | ||
| Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression | Q68095064 | ||
| Replacement of T-cell function by a T-cell product | Q68996648 | ||
| Age-associated increase in interleukin 6 in MRL/lpr mice | Q70186709 | ||
| Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal | Q70669912 | ||
| Urinary levels of IL-6 in patients with active lupus nephritis | Q72897022 | ||
| Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients | Q73028013 | ||
| Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity | Q73076877 | ||
| Synthesis and release of B-lymphocyte stimulator from myeloid cells | Q73335981 | ||
| Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis | Q73537465 | ||
| Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis | Q73925571 | ||
| Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor | Q74165056 | ||
| Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus | Q74175872 | ||
| Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. | Q35552018 | ||
| Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy | Q35798125 | ||
| Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice | Q35833886 | ||
| BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population | Q35834649 | ||
| The Toll-like receptors: analysis by forward genetic methods | Q36185195 | ||
| Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus | Q36364479 | ||
| Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice | Q36370602 | ||
| Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations | Q36375661 | ||
| TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity | Q36811126 | ||
| Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha | Q36813994 | ||
| A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. | Q36851638 | ||
| Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha | Q36976468 | ||
| Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus | Q36993242 | ||
| Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients | Q36993253 | ||
| B cells flying solo. | Q37049026 | ||
| Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients | Q37052138 | ||
| STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus | Q37070948 | ||
| IL-17 producing CD4+ T cells mediate accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice | Q37141196 | ||
| Systemic IFN-alpha drives kidney nephritis in B6.Sle123 mice | Q37234883 | ||
| Age- and sex-related patterns of serum interferon-alpha activity in lupus families | Q37312612 | ||
| Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus | Q37351240 | ||
| Innate immunity to virus infection. | Q37361448 | ||
| The role of IL-23/IL-17 axis in lupus nephritis | Q37397437 | ||
| Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. | Q37453484 | ||
| Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study | Q37548266 | ||
| Interleukin-17 and systemic lupus erythematosus: current concepts | Q37552021 | ||
| Heterogeneity of B cell responsiveness to interleukin 4, interleukin 6 and low molecular weight B cell growth factor in discrete stages of B cell activation in patients with systemic lupus erythematosus | Q39139639 | ||
| Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies | Q40036932 | ||
| TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts | Q40066472 | ||
| IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. | Q40981417 | ||
| Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. | Q41280965 | ||
| Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms | Q41395974 | ||
| Interleukin 6 and its receptor: ten years later | Q41722189 | ||
| Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals | Q42086334 | ||
| Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice | Q42942093 | ||
| Coupling between B cell receptor and phospholipase C-gamma2 is essential for mature B cell development | Q42945151 | ||
| Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. | Q44427081 | ||
| Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study | Q45099936 | ||
| B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. | Q46001110 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| cytokine | Q212354 | ||
| pathogenesis | Q372016 | ||
| modelling biological systems | Q4299308 | ||
| P304 | page(s) | 365083 | |
| P577 | publication date | 2010-05-06 | |
| P1433 | published in | Journal of Biomedicine and Biotechnology | Q15752146 |
| P1476 | title | Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances | |
| P478 | volume | 2010 |
| Q54349394 | Altered IL-10 and TNF-α production in peripheral blood mononuclear cells of systemic lupus erythematosus patients after Toll-like receptor 2, 4, or 9 activation. |
| Q52886621 | Anti-C1q Autoantibodies from Systemic Lupus Erythematosus Patients Induce a Proinflammatory Phenotype in Macrophages. |
| Q51111004 | Association of extended interleukin-10 promoter haplotypes with disease susceptibility and manifestations in German patients with systemic lupus erythematosus. |
| Q101038873 | Atherosclerotic plaque vulnerability is increased in mouse model of lupus |
| Q33699103 | Atopy in children with juvenile systemic lupus erythematosus is associated with severe disease |
| Q35345025 | B cell-derived IL-10 suppresses inflammatory disease in Lyn-deficient mice |
| Q35768902 | BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year |
| Q41896063 | Comparison of commercial kits to measure cytokine responses to Plasmodium falciparum by multiplex microsphere suspension array technology |
| Q36741210 | Correlation of Serum Soluble Interleukin-7 Receptor and Anti-C1q Antibody in Patients with Systemic Lupus Erythematosus |
| Q37661549 | Cytokines as biomarkers in rheumatoid arthritis |
| Q38666746 | Cytokines in systemic lupus erythematosus: far beyond Th1/Th2 dualism lupus: cytokine profiles. |
| Q54312096 | Decreased microRNA-142-3p/5p expression causes CD4+ T cell activation and B cell hyperstimulation in systemic lupus erythematosus. |
| Q45928071 | Decreased serum interleukin 27 in Brazilian systemic lupus erythematosus patients. |
| Q38806513 | Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies |
| Q47770126 | Effects of tetra-arsenic tetra-sulfide on BXSB lupus-prone mice: a pilot study |
| Q87386979 | Elevated levels of serum sCXCL16 in systemic lupus erythematosus; potential involvement in cutaneous and renal manifestations |
| Q35921093 | Genetics of serum concentration of IL-6 and TNFα in systemic lupus erythematosus and rheumatoid arthritis: a candidate gene analysis |
| Q35675014 | HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response. |
| Q26771801 | HTLV-1, Immune Response and Autoimmunity |
| Q37679294 | IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role. |
| Q50090365 | Identification of new type I interferon-stimulated genes and investigation of their involvement in IFN-β activation. |
| Q34614005 | Increased interleukin-23 receptor(+) T cells in peripheral blood mononuclear cells of patients with systemic lupus erythematosus |
| Q46252278 | Increased lipid and protein oxidation and lowered anti-oxidant defenses in systemic lupus erythematosus are associated with severity of illness, autoimmunity, increased adhesion molecules, and Th1 and Th17 immune shift. |
| Q36951816 | Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. |
| Q33598493 | Macrophage migration inhibitory factor: association of -794 CATT5-8 and -173 G>C polymorphisms with TNF-α in systemic lupus erythematosus. |
| Q37626256 | MicroRNA-let-7a promotes E2F-mediated cell proliferation and NFκB activation in vitro |
| Q54389900 | NFKBIL1 confers resistance to experimental autoimmune arthritis through the regulation of dendritic cell functions. |
| Q45911459 | NK cells dysfunction in systemic lupus erythematosus: relation to disease activity. |
| Q55400853 | Non-erythropoietic erythropoietin-derived peptide protects mice from systemic lupus erythematosus. |
| Q36964100 | Protective effects of ethanol extract from Portulaca oleracea L on dextran sulphate sodium-induced mice ulcerative colitis involving anti-inflammatory and antioxidant |
| Q38021183 | Role of TWEAK in lupus nephritis: a bench-to-bedside review |
| Q35986928 | Role of cytokines in systemic lupus erythematosus: recent progress from GWAS and sequencing |
| Q36923701 | STAT3 Signaling in B Cells Is Critical for Germinal Center Maintenance and Contributes to the Pathogenesis of Murine Models of Lupus |
| Q50043197 | Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease. |
| Q35666611 | Serum interleukin-17 levels are associated with nephritis in childhood-onset systemic lupus erythematosus |
| Q38241605 | TNF receptors: signaling pathways and contribution to renal dysfunction |
| Q34262107 | TRIM13 is a negative regulator of MDA5-mediated type I interferon production |
| Q55025713 | The Modulatory Roles of N-glycans in T-Cell-Mediated Autoimmune Diseases. |
| Q38085206 | The applied basic research of systemic lupus erythematosus based on the biological omics. |
| Q85855326 | The protective effect of GM-CSF on serum-induced neutrophil apoptosis in juvenile systemic lupus erythematosus patients |
| Q37849465 | The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis. |
| Q50041410 | Therapeutic potential of DCB-SLE1, an extract of a mixture of Chinese medicinal herbs, for severe lupus nephritis |
| Q35899185 | Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark |
| Q35631769 | Use of laser microdissection in the analysis of renal-infiltrating T cells in murine lupus |
| Q92314457 | miR-98 Modulates Cytokine Production from Human PBMCs in Systemic Lupus Erythematosus by Targeting IL-6 mRNA |
Search more.